{"contentid": 488161, "importid": NaN, "name": "Syncona cornerstones $148 million Series C financing in Gyroscope", "introduction": "Life sciences investment trust Syncona has invested $42.3 million UK-based Gyroscope Therapeutics, a clinical-stage gene therapy company focused on diseases of the eye, in an $148.0 million (\u00c2\u00a3107.8 million) Series C financing.", "content": "<p>Life sciences investment trust Syncona (LSE: SYNC) has invested $42.3 million UK-based Gyroscope Therapeutics, a clinical-stage gene therapy company focused on diseases of the eye, in an $148.0 million (&pound;107.8 million) Series C financing.</p>\n<p>The financing was led by Forbion&rsquo;s Growth Opportunities Fund and also brought in investment from global institutional investors including Sofinnova Investments, Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma and Cambridge Innovation Capital.</p>\n<p>Following the financing, Syncona&rsquo;s holding value in Gyroscope has been written up to &pound;150.6 million, representing an uplift of &pound;37.9 million (5.6 pence per share). Syncona's ownership stake in the business is now 54%. &nbsp;</p>\n<h2><strong>Proceeds will help progress lead candidate GT005</strong></h2>\n<p>This financing will enable Gyroscope to advance clinical development of GT005, the company&rsquo;s lead investigational gene therapy being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).</p>\n<p>GT005 has received Fast Track designation from the US Food and Drug Administration and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with GA. These funds will also enable Gyroscope to further advance its early-stage pipeline and innovative delivery technology, including its proprietary Orbit subretinal delivery system, which is designed for precise delivery to the back of the eye.</p>\n<p>Gyroscope has recently announced positive interim data from the Phase I/II FOCUS trial, showing that GT005 was well tolerated in patients and resulted in sustained increases in Complement Factor I as well as down-regulation of an overactive complement system - a part of the inflammatory system which has been strongly linked as a cause of dry AMD.</p>", "date": "2021-03-26 11:04:00", "meta_title": "Syncona cornerstones $148 million Series C financing in Gyroscope", "meta_keywords": "Syncona, Gyroscope Therapeutics, Series C, Financing, GT005, Macular degeneration, AMD", "meta_description": "Syncona cornerstones $148 million Series C financing in Gyroscope", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-26 11:02:55", "updated": "2021-03-26 11:11:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/syncona-cornerstones-148-million-series-c-financing-in-gyroscope", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "syncona_large.png", "image2id": "syncona_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Gene therapy", "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Ophthalmics, Rare diseases", "topic_tag": "Business Financing, Companies, mergers and acquisitions, Research", "geography_tag": "UK", "company_tag": "Gyroscope Therapeutics, Syncona", "drug_tag": "GT005", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-26 11:04:00"}